| P2093 | author name string | Evangelos Terpos | |
| | Meletios-Athanassios Dimopoulos | |
| | Dimitrios Christoulas | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 |
| | Osteoimmunology: interactions of the bone and immune system | Q24655113 |
| | Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL | Q24682139 |
| | Denosumab in postmenopausal women with low bone mineral density | Q28298728 |
| | OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor | Q34466526 |
| | Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling | Q34546256 |
| | The role of the immune system in the pathophysiology of osteoporosis | Q36324969 |
| | TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 |
| | Functions of RANKL/RANK/OPG in bone modeling and remodeling | Q36700779 |
| | Myeloma bone disease and proteasome inhibition therapies. | Q36818075 |
| | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 |
| | The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma | Q36870585 |
| | TRAFs in RANK signaling | Q36882616 |
| | RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism | Q37108966 |
| | Gut, inflammation and osteoporosis: basic and clinical concepts | Q37137185 |
| | Osteoclast lineage and function | Q37142835 |
| | Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis | Q40038407 |
| | RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes | Q40050213 |
| | Multiple genetic loci for bone mineral density and fractures | Q43870049 |
| | Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index | Q44032751 |
| | Osteoprotegerin to soluble receptor activator of nuclear factor kappa-B ligand ratio is reduced in patients with thalassaemia-related osteoporosis who receive vitamin D3. | Q46389765 |
| | Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells | Q56453539 |
| | Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor–κB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton | Q57904787 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1265-1269 | |
| P577 | publication date | 2008-10-29 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL) | |
| P478 | volume | 18 | |